|View printer-friendly version|
|September 03, 2004 5:16 p.m.|
|Teva Board Of Directors Authorizes The Repurchase Of Up To $300 Million Of Teva Securities|
Jerusalem, Israel, September 3, 2004 - Teva Pharmaceutical Industries Ltd. (Nasdaq: TEVA) announced today that its Board of Directors has authorized the Company to purchase up to an aggregate of $300 million worth of its ordinary shares/ADRs and the convertible debentures of its finance subsidiaries in open market transactions from time to time. The timing of repurchases and the exact number of securities to be purchased will depend upon prevailing market conditions and other factors. Repurchases under this program will be made using the Company's own cash resources and may be commenced or suspended at any time or from time-to-time. Any such market purchases will be effected under the supervision of a special committee of the Board.